LONDON, March 6, 2017 /PRNewswire/ --
Norgine B.V. announced today that it has entered into an agreement with Noventure S.L., under which Norgine will distribute GELSECTAN® in Spain, Portugal and Andorra.
GELSECTAN® is a Class IIa CE marked medical device used as a treatment for irritable bowel syndrome (IBS) with diarrhoea. Diarrhoea is one of the symptoms often associated with irritable bowel syndrome. GELSECTAN® is available in capsules for oral use.
IBS affects up to 7.8% of the total Iberian population (Spain, Portugal and Andorra) and more than 100,000 new cases are reported every year.[i] Women are twice likely as men to develop IBS.[ii]
Peter Martin, COO at Norgine said: "We are delighted to be able to offer GELSECTAN®, a new treatment option to patients who suffer from irritable bowel syndrome (IBS) associated with diarrhoea, a condition which can have a significant impact on quality of life."
He added: "This recent partnership demonstrates our commitment to sell further specialised innovative products through our well established infrastructure."
Luciano Conde, CEO of Noventure, said: "GELSECTAN® is an innovative product that will help to improve the lives of patients across the Iberian Peninsula. We are delighted to partner with Norgine, a recognised leader in the treatment of gastrointestinal diseases with a well-established presence in Spain and Portugal."
Norgine anticipates launching GELSECTAN® in Iberia in the second half of 2017. Noventure will manufacture GELSECTAN®.
Financial terms are not disclosed.
Access full media release on http://www.norgine.com
i. Miguel a Montoro. Gastroenterologia y hepatologia. Problemas comunes en la practica clinica. 2012
ii. Mearin et al. Med Clin (Barc.) 2007; 128 (9):335-43
Norgine Media Contacts:
SOURCE Norgine B.V.